Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective
Purpose. To evaluate the cost-effectiveness of denosumab versus other osteoporotic treatments in older men with osteoporosis from a US payer perspective. Methods. A lifetime cohort Markov model previously developed for postmenopausal osteoporosis (PMO) was used. Men in the model were 78 years old,...
Saved in:
| Main Authors: | Stuart Silverman, Irene Agodoa, Morgan Kruse, Anju Parthan, Eric Orwoll |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Osteoporosis |
| Online Access: | http://dx.doi.org/10.1155/2015/627631 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Osteoporosis in Men
by: Pawel Szulc, et al.
Published: (2012-01-01) -
Advances in the Study of Denosumab Treatment for Osteoporosis and Sarcopenia in the Chinese Middle-Aged and Elderly Population
by: Li S, et al.
Published: (2024-12-01) -
Denosumab is the first gene engineered agent for the treatment of osteoporosis
by: O A Nikitinskaya, et al.
Published: (2012-09-01) -
A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis
by: Yasumori Sobue, et al.
Published: (2025-07-01) -
Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)
by: N. Yu. Velts, et al.
Published: (2024-07-01)